We are live on ! Find out more
CLGN icon

CollPlant Biotechnologies
CLGN

2 hedge funds and large institutions have $52K invested in CollPlant Biotechnologies in 2019 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 2 → 2 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0.01% less ownership

Funds ownership: 0.01% → 0% (-0.01%)

93% less capital invested

Capital invested by funds: $781K → $52K (-$729K)

Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$58.4K
2
UBS Group
UBS Group
Switzerland
+$9.34K

Top Sellers

Rank Fund Capital Flow
1
MIH
Meitav Investment House
Israel
-$780K
2
HIIFS
Harel Insurance Investments & Financial Services
Israel
-$1K

CLGN Hedge Fund Activity: Q2 2019 in Review

2 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in CollPlant Biotechnologies (CLGN) for Q2 2019, worth a combined $52K — down 93% from $781K a quarter earlier.

Fund positioning in CLGN was balanced in Q2 2019: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 0 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $58.4K. The largest seller was Meitav Investment House, exiting entirely with an estimated $780K sold.

  • 2 institutional investors held CollPlant Biotechnologies (CLGN) as of Q2 2019, unchanged from Q1 2019.
  • Funds reported $52K of CollPlant Biotechnologies stock for Q2 2019, down 93% quarter-over-quarter.
  • 2 funds opened new CollPlant Biotechnologies positions in Q2 2019 and 2 closed out, a net change of 0 holders.
  • The largest CollPlant Biotechnologies buyer in Q2 2019 was Citadel Advisors, an estimated $58.4K added.
  • The largest CollPlant Biotechnologies seller in Q2 2019 was Meitav Investment House, an estimated $780K sold.

Based on aggregated 13F filings for Q2 2019.